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Background: Serum Krebs von den Lungen-6 (KL-6), which is classified as human mucin-1 (MUC1), is used as a
marker of sarcoidosis and other interstitial lung diseases. However, there remain some limitations due to a lack of
information on the factors contributing to increased levels of serum KL-6. This study was designed to investigate
the factors contributing to increased levels of serum KL-6 by molecular analysis.
Methods: Western blot analysis using anti-KL-6 antibody was performed simultaneously on the bronchoalveolar
lavage fluid (BALF) and serum obtained from 128 subjects with sarcoidosis.
Results: KL-6/MUC1 in BALF showed three bands and five band patterns. These band patterns were associated
with the MUC1 genotype and the KL-6 levels. KL-6/MUC1 band patterns in serum were dependent on molecular
size class in BALF. Significantly increased levels of serum KL-6, serum/BALF KL-6 ratio and serum soluble interleukin
2 receptor were observed in the subjects with influx of high molecular size KL-6/MUC1 from the alveoli to blood
circulation. The multivariate linear regression analysis involving potentially relevant variables such as age, gender,
smoking status, lung parenchymal involvement based on radiographical stage and molecular size of KL-6/MUC1 in
serum showed that the molecular size of KL-6/MUC1 in serum was significant independent determinant of serum
KL-6 levels.
Conclusions: The molecular structural variants of KL-6/MUC1 and its leakage behavior affect serum levels of KL-6 in
sarcoidosis. This information may assist in the interpretation of serum KL-6 levels in sarcoidosis.
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Krebs von den Lungen-6 (KL-6) is a mucinous sialylated
sugar chain on human mucin-1 (MUC1) [1,2]. MUC1 con-
sists of a large extracellular domain, a single-pass trans-
membrane region, and an intracellular cytoplasmic tail
[3,4]. The large extracellular domain contains a variable
number of tandem repeat (VNTR) regions that are heavily
glycosylated (Figure 1). In normal lung tissue, KL-6 is
expressed on type II pneumocytes [1,5]. KL-6 is present in
high concentrations in bronchoalveolar lavage fluid (BALF)
and also circulates in blood [6]. Serum KL-6 is specifically* Correspondence: nasuhara@med.hokudai.ac.jp
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distribution, and reproduction in any mediumelevated in a majority of patients with interstitial lung dis-
eases (ILDs), and this phenomenon is considered to reflect
the production by regenerating type II epithelial cells based
on disease activity [6-13]. Therefore, measurement of
serum KL-6 is widely accepted, particularly in Japan, as a
diagnostic test for ILDs and a marker of disease activity.
Sarcoidosis is a multiorgan inflammatory disease of
unknown origin that is characterized by noncaseating
epithelioid cell granuloma and lymphocytic alveolitis [14].
Because the natural history and prognosis of sarcoidosis
are unpredictable, it is important to monitor disease
development during management [14]. KL-6 is considered
to be one of the useful serum markers for monitoring
diseases activity in sarcoidsis. Several investigators have
reported that levels of serum KL-6 reflect lymphocytic
alveolitis and increased parenchymal infiltration [11-13].
However, we have experienced some limitations in thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Possible diagrammatic structure of MUC1 showing KL-6 epitopes. TM, transmembrane; VNTR, variable number of tandem repeats.
Arrows indicate KL-6 antigens on MUC1 protein.
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dissociation with disease activity and different behavior
from other serum markers in some cases. This prompted
us to examine the factors contributing to increased levels
of serum KL-6.
There are known variations in the length and structure of
the MUC1 protein that result from polymorphisms in the
VNTR [15,16]. The size class of MUC1 protein in tears is
reported to be linked with the genotype of a single nucleo-
tide polymorphism (SNP) in exon 2 (rs4072037) of the
MUC1 gene [16]. In addition, Janssen et al. recently
reported an association between this polymorphism and
variations in serum KL-6 levels in healthy individuals and
patients with pulmonary sarcoidosis [17]. Based on these
reports, we hypothesized that: 1) various molecular sizes of
KL-6/MUC1, which are genetically determined by MUC1
gene polymorphism (such as rs4072037), would be present
in BALF; 2) the influx of KL-6/MUC1 from alveoli to blood
is dependent on the molecular size of KL-6/MUC1; and
finally, 3) serum KL-6 levels would be affected by the
molecular size and leakage behavior of KL-6/MUC1, in
addition to increased local production of KL-6/MUC1 in
lung.
In this study, we examined the factors contributing to the
variable increases in serum levels of KL-6 using molecular
analysis in patients with sarcoidosis, all of whom simultan-
eously underwent blood sampling and bronchoalveolar
lavage (BAL).Materials and methods
Subjects
A total of 128 subjects with pulmonary sarcoidosis visit-
ing the pulmonary clinic of the First Department of
Medicine, Hokkaido University Hospital between April2000 and July 2011 were enrolled into this study. The
diagnosis of pulmonary sarcoidosis was established
based on clinical findings and histologic evidence of
noncaseating epithelioid cell granulomas, after excluding
known causes of granulomatous diseases, in accordance
with the American Thoracic Society/European Respira-
tory Society/World Association of Sarcoidosis and other
Granulomatous Disorders guidelines [14]. All subjects
underwent BAL, which is a routine diagnostic procedure
at our hospital for patients with undiagnosed sarcoidosis,
as described previously [18,19]. Serum samples were
collected 30 minutes before BAL in all subjects. The study
population, sex, age, smoking history, radiographical stage
[14], BALF findings, pulmonary functions results, and
levels of serum markers are shown in Table 1. The smok-
ing status of one subject was unknown. BALF cell analysis
of 1 patient was not performed due to problems with BAL
storage. Pulmonary function data were available from 122
patients.
All patients had provided written informed consent for
their samples to be used in future clinical research
[18,19]. The Institutional Review Board of Hokkaido
University Hospital for Clinical Research approved the
study protocols (approval No. 009–0295).Western Blotting
Western blotting was performed on BALF and serum
from all subjects. Briefly, protein samples from BALF
and serum were electrophoresed on 3%–8% NUPAGE
Tris-acetate gels (Invitrogen, Carlsbad, CA) and were
transferred to nitrocellulose membranes (Invitrogen).
Membranes were blocked with PBS containing 3% skim
milk. Western blot analysis was performed using anti-
KL-6 antibody (anti-KL-6 antibody was kindly provided
Table 1 Characteristics of the study population
Sarcoidosis










Total cell counts, 104/mL 18.1 (3.2–92.2)
Macrophages, % 66.3 (6.0–97.0)
Lymphocytes, % 32.8 (2.9–76.3)
CD4/CD8, ratio 4.93 (0.65–30.16)
Pulmonary function result
VC, % predicted 113.0 (70.5–153.7)
DLco, % predicted 90.1 (37.0–142.0)
Serum maker
soluble IL-2 receptor, U/mL 805 (117–4990)
KL-6 levels
BALF, U/mL 296 (90–1507)
serum, U/mL 336 (102–3091)
Data are presented as median (range).
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Cruz Biotechnology, Santa Cruz, CA) followed by alka-
line phosphatase-conjugated goat anti-mouse Ig. Bands
were developed using the WesternBreeze Chromogenic
Immunodetection Kit (Invitrogen).
Genotyping of MUC1 polymorphism
The MUC1 SNP (exon 2; rs4072037) was genotyped in 80
patients with sarcoidosis, who had consented to future
genetic studies, using the TaqMan system (Assay ID:
C_27532642_10, Applied Biosystems, Foster City, CA).
Measurement of KL-6, albumin and soluble interleukin 2
receptor
KL-6 levels in both BALF and serum were measured by
electrochemiluminescent immunoassay using the PICO-
LUMI KL-6 kit (Sanko Junyaku, Tokyo, Japan). Reference
intervals were 105.3–401.2 U/mL for Japanese normal
subjects. Albumin levels in BALF were measured on a
Hitachi 7070 automated analyzer with TAC-2 test Albu-
min U (Medical and biological laboratories co., LTD.,
Nagoya, Japan). Serum soluble interleukin 2 (IL-2) recep-
tor was measured by a solid-phase, two-site chemilumin-
escent immunometric assay (IMMULITE 2000 IL2R,
Siemens Healthcare Diagnostics, Los Angeles, CA).Statistical methods
Statistical analysis was performed with SYSTAT 11 for
Windows (Systat Inc., Chicago, IL) and SAS (SAS Insti-
tute, Inc., Cary, NC). Data were expressed as median
and ranges. All data were not normally distributed on
univariate analysis, the natural logarithm of all data were
used for further statistical analyses. Comparisons were
performed by unpaired t-test or ANOVA adjusting
potentially relevant variable such as cigarette smoking
when assessing the influence of smoking status (never,
ex or current). Differences between groups were evalu-
ated by ANOVA and were assessed by Bonferroni post-
hoc test. The relationship between leakage behavior of
KL-6/MUC1 and smoking status was assessed using χ2-
test. Correlations between different parameters were
determined by Pearson’s correlation coefficient. We used
Haploview software version 4.1 (http://www.broad.mit.
edu/mpg/haploview; Barrett et al. 2005) in order to
compare the observed numbers of genotypes with the
number of expected genotypes under Hardy-Weinberg
equilibrium using χ2-test. The association between MUC1
genotypes and KL-6/MUC1 band patterns in BALF was
assessed using Cochran-Mantel-Haenszel Statistics. In
order to identify independent factors predictive for the
serum KL-6 levels, the multivariate linear regression ana-
lysis involving potentially relevant variables was per-
formed. A p value of <0.05 was regarded as significant.
Results
Western blot analysis
Western blot analysis of BALF with anti-KL-6 antibody
revealed three bands (low molecular size (L), middle mo-
lecular size (M) and high molecular size (H), at approxi-
mately 400, 450 and 500 kDa, respectively) under
reducing conditions. Furthermore, based on the combin-
ation of these bands, five band patterns (L alone, L/M,
L/H, M/H and H alone) were identified (Figure 2A). In
addition, Western blot analysis with DF-3 antibody
showed the same band patterns corresponding to the
KL-6/MUC1 band patterns in BALF (Figure 3). All Sub-
jects who displayed the L alone pattern in BALF also
displayed L alone bands in serum (Figure 2B; Sar 1). On
the other hand, subjects who displayed non-L alone pat-
terns in BALF showed diverse patterns in serum. Based
on the similarities and differences in band patterns
between BALF and serum, we classified these subjects
into two groups; “non-leakage” and “leakage”. The non-
leakage group displayed only L bands or neither M nor
H bands in serum, despite the presence of M or H bands
in BALF (Figure 2B; Sar 2, 3 and 4). In contrast, the leak-
age group displayed identical band patterns between BALF
and serum (Figure 2B; Sar 5, 6 and 7). The frequency and
percentage of KL-6/MUC1 band patterns in BALF and in
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Figure 2 A. Representative examples of Western blot analyses using anti-KL-6 antibody in BALF. Three bands were detected under
reducing conditions with low (L), middle (M) and high molecular weights (H), corresponding to approximately 400, 450 and 500 kDa, respectively.
Based on the three bands, there were five band patterns (L alone, L/M, L/H, M/H, H alone) identified in 128 subjects with sarcoidosis. B.
Comparison of KL-6/MUC1 band patterns between BALF and serum in 7 representative subjects. Sar, subjects with sarcoidosis. Arrows
indicate M or H bands present in serum.
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Figure 3 Representative examples of Western blot analysis using ant
DF-3 antibody. Arrows indicate L, M or H bands.KL-6/MUC1 (i.e., M or H band) appeared to be influenced
by smoking status (never, ex or current), but it did not
reach statistical significance (χ2-test, p> 0.05) (Table 3).BALF1 BALF2 BALF3
DF-3 anitibody
L/L L/M L/H
i-KL-6 antibody and DF-3 antibody in BALF. A, anti-KL-6 antibody; B,
Table 2 The frequency and percentage of KL-6/MUC1 band patterns in between BALF and serum
Band pattern in serum
TotalL alone L/M L/H H alone Not detected
Band pattern in BALF L alone 81 81
100.0% 100.0%
Non L alone L/M 8 * 8 ** 16
50.0% 50.0% 100.0%
L/H 18 * 6 ** 24
75.0% 25.0% 100.0%
M/H 3 * 3
100.0% 100.0%
H alone 2 ** 2 * 4
50.0% 50.0% 100.0%
Total 107 8 6 2 5 128
83.6% 6.3% 4.7% 1.6% 3.9% 100.0%
*, non-leakage group; **, leakage group.
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BALF KL-6 levels in subjects with the H alone or M/H,
L/H and L/M patterns in BALF were significantly higher
than those with the L alone pattern in BALF (p< 0.001,
<0.001 and 0.003, respectively) (Figure 4A), thus suggesting
that larger molecular size of KL-6/MUC1 is associated with
higher levels of BALF KL-6. Similarly, serum KL-6 levels in
subjects with the L/H pattern in serum were significantly
higher than those with the L alone pattern (p< 0.001)
(Figure 4B).
Relationship between MUC1 genotypes and KL-6/MUC1 size
We examined the allele frequency of rs4072037. There
was 129 (80.6%) for A and 31 (19.4%) for G. The genotype
frequencies were 53 (66.3%) for AA, 23 (28.7%) for AG,
and 4 (5.0%) for GG. No significant deviation from the
Hardy-Weinberg equilibrium was observed (p> 0.05).
When the KL-6 levels in both serum and BALF were
grouped according to the genotype, the results were AA
(serum: 285U/mL, 102–2627; BALF: 240U/mL, 90–1224),Table 3 Relationship between leakage behavior of high
molecular size KL-6/MUC1 and smoking status














Total 31 16 47
66.0% 34.0% 100.0%
X2-test, p> 0.05.AG (serum: 480U/mL, 183–3091, BALF: 662U/mL, 130–
1336) and GG (serum: 437U/mL, 337–1600; BALF: 444U/
mL, 219–633) The KL-6 levels in both serum and BALF
from the subjects with AG genotype were higher than
those with AA genotype (p< 0.001, <0.001, respectively).
Table 4 shows the relationship between MUC1 genotypes
and KL-6/MUC1 band patterns in BALF. There is a
significant relationship between genotype and KL-6/
MUC1 band patterns in BALF (Cochran-Mantel-Haenszel
Statistics, p< 0.001); the A allele is linked with L bands
and the G allele with H bands.
Determination of leakage behavior of high molecular size
KL-6/MUC1
As the subjects who displayed non-L alone patterns in
BALF showed diverse band patterns in serum, we exam-
ined the presence of differences in the leakage behavior of
high molecular size KL-6/MUC1 (i.e., M or H band). We
compared the serum KL-6 levels, the serum/BALF KL-6
ratio, the BALF albumin levels, the numbers of lympho-
cytes and CD4 positive cells in BALF and the serum soluble
IL-2 receptor levels between the non-leakage and the leak-
age groups. As expected, the serum KL-6 levels in the
leakage group were significantly higher than those in the
non-leakage group (p=0.023, Figure 5A). In addition, there
was a significant increase in the serum/BALF KL-6 ratio in
the leakage group, when compared with the non-leakage
group (p=0.002, Figure 5B). This result remained signifi-
cant even after controlling for the smoking status
(ANOVA, p=0.005). In contrast, no significant differences
in the BALF albumin levels between the non-leakage and
the leakage groups were observed (p=0.510, Figure 5C).
The leakage group tended to have the slightly higher num-
bers of lymphocytes and CD4 positive cells in BALF than

































Figure 4 A. Comparison of KL-6 levels in BALF based on KL-6/MUC1 band pattern in BALF. B. Comparison of KL-6 levels in serum
based on KL-6/MUC1 band pattern in serum.
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levels in the leakage group was significantly higher than
the non-leakage group (p=0.026, Figure 5F).
Impact of KL-6/MUC1 molecular structural variants on
serum KL-6 levels
Recent reports have shown that serum KL-6 levels may be
affected by several potential factors, such as age, gender
and smoking status, other than lung diseases [17,20]. In
addition, previous reports have found that radiographical
staging showing parenchymal involvement (stages II and
higher) is correlated with significantly higher KL-6 levels,
as compared to patients without parenchymal involvementTable 4 Relationship between MUC 1 gene polymorphism
(rs4072037) and KL-6/MUC 1 band patterns in BALF
KL-6/MUC1 band pattern in BALF
L alone L/M L/H M/H H alone Total
rs4072037 AA 47 5 1 53
88.7% 9.4% 1.9% 100.0%
AG 1 6 15 1 23
4.3% 26.1% 65.2% 4.3% 100.0%
GG 1 1 2 4
25.0% 25.0% 50.0% 100.0%
Total 48 11 17 2 2 80
60.0% 13.8 21.3% 2.5% 2.5% 100.0%
Cochran-Mantel-Haenszel Statistics, p< 0.001.(stages 0 and I) [10-12]. In univariate analyses between
serum KL-6 levels and potentially relevant variables, there
were significant differences between the subjects without
and with lung parenchymal involvement based on radiogra-
phical stage [14] (p=0.020) and those with low and higher
molecular size KL-6/MUC1 in serum (p< 0.001) (Table 5).
In order to identify independent factors predictive for the
serum KL-6 levels, the multivariate linear regression analysis
involving potentially relevant variables such as age (years),
gender (male or female), smoking status (never, ex or
current), lung parenchymal involvement (without or with
parenchymal infiltration) and molecular size of KL-6/MUC1
in serum (low or higher molecular size) was performed. The
multivariate linear regression analysis showed that only
molecular size of KL-6/MUC1 in serum (Standardized β
coefficient=0.365, p< 0.001) was significant independent
determinant of serum KL-6 levels (Table 6).
Discussion
The increased levels of serum KL-6 in patients with ILDs
are thought to result from an increased local production of
KL-6/MUC1 in lung and enhanced permeability following
the destruction of the alveolar-blood interface [5,21]. In this
study, we discovered three important findings with regard
to the factors contributing to the variably in serum levels of
KL-6. First, KL-6/MUC1 in BALF showed three bands and
five band patterns, and these band patterns were associated





























































































































Figure 5 A, B, C, D, E and F. Comparison of serum KL-6 levels, serum/BALF KL-6 ratio, BALF albumin levels, number of lymphocytes
and CD4 positive cells in BALF and serum soluble IL-2 receptor levels between non-leakage and leakage in subjects who displayed
non-L alone band pattern in BALF.
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lar size class in BALF, as proteins of different size classes did
not pass through the alveolar-blood interface in a similar
manner. Finally, the molecular structural variants of KL-6/
MUC1 and its leakage behavior affect serum KL-6 levels.
We believe that what we found in this study would provide
new insight into understanding the limitations related to the
measurement of serum KL-6.
Before further discussion on these issues, we should
comment on the limitations of this study. It is possible
that the size classes of KL-6/MUC1 detected by Western
blot analysis using anti-KL-6 antibody were affected by
glycosylation of MUC1, and may not strictly reflect mo-
lecular weight. However, Western blot analysis using
DF-3 antibody, which recognize the core peptide of
MUC1 [22,23], displayed the same band patterns, sug-
gesting that the glycosylation of MUC1 had little influ-
ence on the molecular size of KL-6/MUC1 characterized
by Western blot analysis using anti-KL-6 antibody. We
could not examine the local production of KL-6/MUC1and quantitatively analyze each molecular size of KL-6/
MUC1 in this study. The local production of KL-6/
MUC1 may still be important for the interpretation of
serum KL-6 levels.
The larger MUC1 proteins may express more KL-6 on
its surface than the smaller MUC1 proteins. In this
study, KL-6 levels in BALF, which are little influenced
with alveolar-blood interface, from the subjects with lar-
ger molecular size of KL-6/MUC1 (i.e. M and H band)
were significantly higher than those with low molecular
size (i.e. L band). Janssen et al. reported that the MUC1
genotype was of strong influence on serum KL-6 levels
in the Caucasian population and also speculated that the
positive association between MUC1 gene polymorphism
and serum KL-6 levels is caused by MUC1 allele-related
molecular size. The MUC1 genotype was clearly linked
with KL-6/MUC1 band pattern and related to KL-6
levels in our study. Therefore, KL-6 levels are affected by
genetically determined molecular sizes of KL-6/MUC1.
Furthermore, our results showed that significantly
Table 5 Univariate analyses between Log serum KL-6 and
potentially relevant variables




Gender Male 2.57 ± 0.237
0.726
Female 2.56 ± 0.264
Smoking status Non/Ex smoker 2.54 ± 0.205
0.072
Current smoker 2.62 ± 0.302
Lung parenchymal
involvement
Without 2.53 ± 0.198
0.020










* Pearson correlation coefficient; ** unpaired t-test.
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jects with influx of high molecular size KL-6/MUC1 from
the alveoli to blood circulation. This is the first reports
describing the influence of leakage behavior of high mo-
lecular size KL-6/MUC1 on serum KL-6 levels. Consider-
ing for the molecular size of KL-6/MUC1 and its leakage
behavior may increase the value of serum KL-6 as a mar-
ker of sarcoidosis.
With regard to MUC1 gene polymorphism and KL-6/
MUC1 band patterns in BALF, although the A allele was







Smoking status 0.087 0.353
Lung Parenchymal involvement* 0.125 0.164
Molecular size of KL-6/MUC1 in serum 0.365 <0.001
* Based on radiographical stage.the H band, 5 of 53 subjects (9.4%) with the AA geno-
type, 7 of 23 subjects (30.4%) with the AG genotype and
1 of 4 subjects (25.0%) with the GG genotype exhibited
the M band. MUC1 alleles can mostly be divided into
size classes containing small (30–45) or large (60–90)
numbers of repeats on Southern blot analysis [15,24]. In
other words, the molecular size of the protein, which
directly reflects the allele length, is associated with the
number of tandem repeats on VNTR regions. We thus
speculate that the presence of M bands in BALF indi-
cates the presence of intermediate numbers of tandem
repeats in VNTR regions.
Influx mechanism of KL-6/MUC1 from the alveoli to
blood circulation is unclear. In sarcoidosis, increased
levels of BALF albumin are thought to result from an in-
flux of plasma albumin into the alveoli [25]. To analyze
the leakage behavior of high molecular size KL-6/
MUC1, we also measured the concentration of BALF
albumin in subjects with non-L alone pattern in BALF.
No significant differences between the groups of non-
leakage and leakage of high molecular size KL-6/MUC1
were observed in the BALF albumin levels. In contrast,
there was a significant increase in the serum/BALF KL-6
ratio, which is an indicator of leakage behavior, in the leak-
age group. The influx of the high molecular size KL-6/
MUC1 may be not parallel to albumin-size proteins and
be complicated.
The passage of high molecular size KL-6/MUC1 from
alveoli to blood may be regulated by pore size and/or
electrostatic forces [26-29]. In an isolated dog lung, Con-
haim et al. proposed that the lung epithelial barrier is
best described by a three-pore-size model, including a
very small number of large pores (400-nm radius), an
intermediate number of medium-size pores (40-nm ra-
dius), and a very large number of small pores (1.3-nm
radius) [28]. If such a theory could be extrapolated to
the human lung, it is possible that high molecular size
KL-6/MUC1 passes through the alveolar-blood interface,
considering that the molecular diameter of KL-6/MUC1
is approximately 200–500 nm [4]. A number of studies
have indicated that the surfaces of endothelium, epithe-
lium and basement membranes are covered by negatively
charged proteoglycans. Under such conditions, electro-
static forces would affect the movement of charged versus
uncharged macromolecules [29,30]. As most lung proteins,
particularly mucins, are negatively charged at physiologic
pH [31,32], it is very plausible that similar electrostatic
repulsion influences their transfer from lung into blood.
Hence, we speculate that electrostatic forces would limit
the transfer of high molecular size KL-6/MUC1 more
efficiently at the alveolar-blood interface, as compared to
small molecular size, under healthy conditions. However, if
such barrier function is damaged, the high molecular
size proteins would more easily pass through the alveolar
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in BALF tended to be elevated and the serum IL-2 receptor
levels were significantly increased in the subjects in which
the influx of the high molecular size KL-6/MUC1 was
observed. The percentage of lymphocytes in BALF is
thought to be a marker of alveolitis [33,34]. Soluble IL-2 re-
ceptor was reported to be associated with T-lymphocyte al-
veolitis [35] . Our results suggest that high molecular size
KL-6/MUC1 might transfer from the alveoli to blood circu-
lation as a result of alveolitis.
Cigarette smoke exposure is known to increase the per-
meability of the lung epithelial/endothelial barrier [36,37].
The mechanisms by which cigarette smoke disrupts epi-
thelial integrity have not been fully defined, but are likely
to involve alterations in the function of the tight junctions
[38], which normally maintain the polarity of the epithelial
cells and limit flow of ions and proteins from one side of
the monolayer to the other. In this study, we did not dem-
onstrate statistically significant relationship between
smoking status and the leakage behavior of high molecular
size KL-6/MUC1. The multivariate linear regression ana-
lysis showed that the molecular size of KL-6/MUC1 in
serum was only significantly independent determinant of
serum KL-6 levels. However, there have been a few reports
describing that serum KL-6 levels may be affected by
smoking status in healthy controls [17,20]. Further studies
to analyze relationships between cigarette smoking and
leakage behavior of KL-6/MUC1 and KL-6 levels in
healthy controls would be necessary.
The findings of this study are important for both the in-
terpretation of serum KL-6 levels and the consideration of
serum marker proteins, such as surfactant protein (SP)-D
[39], that originate in lung epithelium and have been iden-
tified in serum from patients with sarcoidosis and other
ILDs. Leth-Larsen et al. reported that SP-D gene poly-
morphism influences the potential for oligomerization,
which results in significantly different SP-D serum levels
[40]. Their data strongly indicates that the passage of
SP-D protein through the alveolar-blood interface is also
dependent on the size of the SP-D protein corresponding
to the gene polymorphism. With regard to serum markers
in lung diseases, the different behaviors among markers
have long been a subject of debate. The molecular size
classes that may be specific to each marker protein could
explain the different behaviors of these proteins in serum.
Finally, it is noteworthy that the minor allele (i.e.,
G allele) frequency of rs4072037 may differ with ethnicity.
In the Caucasian population, Janssen et al. reported that it
was 0.45 [17], which is much higher than our observed
frequency of 0.21, and the frequency in the Japanese popu-
lation reported by HapMap (www.hapmap.org). Thus, the
interpretation of serum KL-6 levels may be more complex
in the Caucasian population than in Japanese population.
This may explain the fact that measurements of KL-6 arenot well accepted as diagnostic markers of sarcoidosis and
other interstitial lung diseases in most Western countries,
in contrast to Japan, where such measurements are rou-
tinely used in various clinical settings.
Conclusions
This study has shown that the molecular structural var-
iants of KL-6/MUC1 and its leakage behavior affect
changes in serum levels of KL-6 in sarcoidosis. This in-
formation will assist in the interpretation of serum KL-6
levels in sarcoidosis. Further studies to examine the fac-
tors contributing to the variable increases in serum
levels of KL-6 using molecular analysis in other ILDs
would be warranted.
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